Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.88 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.88 |
| ▸ | FAP | Q12884 | 2/20 | 0.63 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.63 |
| ▸ | MC4R | P32245 | 1/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.63 |
| ▸ | GHSR | Q92847 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842865 | 1.00 | DPP4 (0.88) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842437 | 0.94 | DPP4 (1.00) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842422 | 0.94 | DPP4 (1.00) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL8354586 | 0.91 | DPP4 (0.71) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842495 | 0.87 | DPP4 (0.85) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL5842486 | 0.87 | DPP4 (0.85) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL2515495 | 0.87 | DPP4 (0.82) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL2515500 | 0.87 | DPP4 (0.82) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL8354649 | 0.84 | DPP4 (0.81) | DPP4CHRM1FAPPOU2F2ADORA3 | |
| SCHEMBL637705 | 0.83 | DPP4 (1.00) | DPP4CHRM1FAPPOU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 552/4885FAP 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.